 |
|
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
October 24, 2007Phase 2 Consortium clinical trial shows promising results
SAN FRANCISCO -- Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.
Findings from this Phase 2 Consortium (P2C) clinical trial were presented by the study's primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer.
"We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising."
More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).
In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapy's effectiveness against platinum-resistant cancers.
Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.
The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.
"We now need to expand this trial to validate these interim results in additional patients," says Dr. Bible. "We're also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer."
Mayo Clinic
"We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising."
More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).
In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapy's effectiveness against platinum-resistant cancers.
Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.
The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.
"We now need to expand this trial to validate these interim results in additional patients," says Dr. Bible. "We're also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer."
Mayo Clinic
Ovarian Cancer Current Events and Ovarian Cancer News RSSDormant cancer cells rely on cellular self-cannibalization to survive
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation.
Study links obesity to elevated risk of ovarian cancer
A new epidemiological study has found that among women who have never used menopausal hormone therapy, obese women are at an increased risk of developing ovarian cancer compared with women of normal weight.
Minimizing obesity's impact on ovarian cancer survival
Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center found ovarian cancer survival rates are the same for obese and non-obese women if their chemotherapy doses are closely matched to individual weight.
Nursing study concludes few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes
An Ontario study of 491 women with invasive ovarian cancer found only a small proportion, 19%, were referred for genetic testing of BRCA1 and BRCA2, the breast cancer genes, which means family members are not informed of their cancer risk.
International study supports new standard of treatment for women with advanced ovarian cancer
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course.
Stanford blood scanner detects even faint indicators of cancer
A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival.
Study unmasks how ovarian tumors evade immune system
Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Disease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
Bio-imaging mass spectrometry techniques reveal molecular details about complex systems
Understanding biology at the systems level is difficult, especially when studying complex specimens like tissue slices or communities of organisms in a biofilm. Scientists must be able to identify, quantify and locate the molecules present in the samples.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
 | A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz, Robert E. Bristow This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the... |
 | 100 Questions & Answers About Ovarian Cancer, Second Edition by Don S. Dizon Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this book offers help. Completely updated, the new second edition of 100 Questions & Answers About Ovarian Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a... |
 | Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and... |
 | Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life by Chris Bledy A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to... |
 | Ovarian Cancer (Patient-Centered Guides) by Kristine Conner, Lauren Langford This unique guide for ovarian cancer gives women crucial medical information to improve the chance for lengthy remission and cure, as well as emotional support for the journey. Although many ovarian cancers are discovered after they have spread, having information about surgery and best practices can be life-saving. For example, choosing a surgeon from the new specialty of gynecologic oncology... |
 | Gilda's Disease: Sharing Personal Experiences and a Medical Perspective on Ovarian Cancer by Steven Piver The first book on ovarian cancer for the general reader, this is a comprehensive, compassionate look at a disease millions of people first became aware of with the tragic death of comedienne Gilda Radner in 1989. Dr. Piver, a leading cancer surgeon, discusses the causes of ovarian cancer, preventative measures, classic signs and symptoms, diagnostic tests and genetic screening, the different... |
 | Ovarian Cancer Medical Guide by Qontro Medical Guides The Ovarian Cancer Medical Guide is a publication which has been designed to better help readers understand Ovarian Cancer. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Ovarian Cancer. The Ovarian Cancer Medical Guide is highly recommended for those interested in understanding and... |
| 2009 Ovarian Cancer (Teal Ribbon) Weekly Planner by Thomas Masterson, MD, Karen Dawn, R.N. Why an Ovarian Weekly Planner? Education and support on your way towards health and vitality. Ovarian cancer is a devastating diagnosis and can criple the spirit. We hope that with the use of this planner, you will track your successes, gain knowledge and... | |
 | Ovarian Cancer: State of the Art and Future Directions in Translational Research (Advances in Experimental Medicine and Biology) Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for... |
 | Cancer and Death: A Love Story in Two Voices (Health Communication) by Leah Vande Berg, Nick Trujillo In this book, Leah and Nick tell the story of their lives together and about how their love for each other sustained them during Leah's 14-month ordeal with Stage IV ovarian cancer. This book is one of the most honest accounts ever written about cancer, death, grief and... |
| © 2009 BrightSurf.com |